Lamellar Biomedical is an innovative biotechnology company developing our proprietary LAMELLASOME™ based therapies to transform the treatment of complex and rare lung disorders, either as biologically active products in their own right or by delivering active payloads. Along with our in-house research and development team, we are collaborating with world-renowned institutions and universities to develop therapeutics that capitalise on the unique properties of LAMELLASOME™ formulations that protect lung tissues.
LAMELLASOME™ technology can be designed to deliver active payloads such as gene therapies, or by utilising intrinsic anti-infective properties which can enhance antibiotics. Lamellar is the only organisation exploiting the biophysical and drug delivery properties of lamellar bodies.
While the alveolar lamellar body (commonly known as surfactant) had been well profiled, Lamellar’s founder James Dobbie pioneered the discovery of the natural serous lamellar body. Given the observed in-life properties of these lamellar bodies, Lamellar created a synthetic mimetic based on their component phospholipids, then successfully demonstrated the mimetic’s biophysical properties on the components of cystic fibrosis (CF) sputum. This novel mimetic was patented as LMS-611 and the technology trademarked as LAMELLASOME™. LAMELLASOME™ have biophysical properties essentially identical to those of a natural lamellar body.
Since 2012, the Company has invested heavily in developing its in-house R&D capabilities to advance pioneering research. In February 2018, the Company moved into bespoke laboratories and offices, advancing the development of LAMELLASOME™ products, and the addition of further laboratory space in 2019 has significantly extended our formulation and processing capabilities.
Lamellar was founded in 2007 and is backed by both institutional and private investors, including Invesco, Scottish Enterprise, Barwell Plc, TRI Capital and has multiple research collaborations with world renowned institutions and universities, such as the University of Edinburgh, the University of Strathclyde’s Institute of Pharmacy and Biomedical Sciences, University of Edinburgh and the University of Freiburg’s Institute of Pharmaceutical Science.
For more information, please visit our Pipeline section or contact us.
Lamellar has a broad product portfolio protected by approved and pending patent families. Rare and serious disease indications will also benefit from Orphan Drug exclusivity, and further IP will be derived from new products.
Lamellar’s patent portfolio has recently expanded to include a promising new LAMELLASOME™ Nucleic Acid Transfer technology and some key products that demonstrate the potential of the technology. For more information, please contact us.
Collaboration & partnerships
Lamellar Biomedical is a member of the Scottish Life Sciences Association (SLA).
The Company has well established partnerships with the University of Edinburgh and the University of Strathclyde to further optimise our LAMELLASOME™ platform and its product manufacturing processes.
Lamellar also have a collaboration with the Institute of Pharmaceutical Science group at the University of Freiburg in Germany. This collaboration supports our LAMELLASOME™ Nucleic Acid delivery platform focussing on aspects of efficient and functional nucleic acid delivery.
We also have an agreement with the Edinburgh Complex Fluids Partnership to advance research into the biophysical properties of LAMELLASOME™.
Grants & awards
The scientific and commercial potential of the LAMELLASOME™ technology has been recognised by the award of two concurrent Knowledge Transfer Partnerships (KTP). The first one was initiated by Lamellar and the Edinburgh Complex Fluids Partnership of Edinburgh University to develop LAMELLASOME™ properties for use in the treatment of CF.
Together with Professor Perrie of Strathclyde University, an internationally recognised professor in drug delivery, we were awarded our second Innovate UK KTP for the process optimisation and characterisation of LAMELLASOME™ formulations.
Lamellar won an MRS PhD studentship with the Roslin Institute for the study of LAMELLASOME™ as an antifibrotic agent, a key property of its lead product IPF-Lamellasome.
The Company has also been successful in attracting major grants to support our in-house research including SMART Scotland, EPSRC IAAs, MRS, SULSA, KTP and BBSRC iCase grants.